Corcept Therapeutics

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corcept Therapeutics (CORT) is leading pharma stocks news on Thursday with approval from the U.S. Patent and Trademark Office's PTAB. The post Pharma Stocks: Why Corcept Therapeutics Stock Is Soaring 24% Today appeared first on InvestorPlace.

Pharma Stocks: Why Corcept Therapeutics Stock Is Soaring 24% Today

MENLO PARK, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a decision upholding the validity of all claims of U.S. Patent No. 10,195,214, “Concomitant Administration of Glucocorticoid Receptor Modulators and CYP3A Inhibitors” (the “‘214 patent”). The ‘214 patent expires in 2037.

U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept's U.S. Patent No.10,195,214

Corcept Therapeutics' (LAUR) CEO Eilif Serck-Hanssen on Q3 2020 Results - Earnings Call Transcript

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Earnings Call Transcript

Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year.

Corcept (CORT) Misses on Q3 Earnings, Tightens 2020 Sales View

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Quick Version Earnings Call Transcript

Corcept (CORT) delivered earnings and revenue surprises of -19.05% and -4.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Lags Q3 Earnings and Revenue Estimates

Shares of Corcept Therapeutics (NASDAQ:CORT) fell 4.49% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 22.58% over the past year to $0.24, which beat the estimate of $0.20.

Corcept Therapeutics: Q3 Earnings Insights

A patent decision on its cortisol therapy Korlym is expected to be rendered next month.

Why Corcept Therapeutics Soared 37% Higher in September

Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well.

Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe

MENLO PARK, Calif., Sept.  10, 2020  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of its first patient in GRATITUDE II, a randomized, double-blind, placebo-controlled, Phase 2 trial of miricorilant in obese patients with schizophrenia and long-standing antipsychotic-induced weight gain (APIWG).

Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant  to Treat Weight Gain Caused by Antipsychotic Medication

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Why Is Corcept (CORT) Up 38.4% Since Last Earnings Report?

Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock?

Athenex

Caleres

DXC Technology

Twitter

The Dow Jones Industrial Average closed at 29,100.50 on Wednesday with a gain of 454.84 points or 1.59%.

US Indexes Report New Closing Records Wednesday

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Corcept Therapeutics, Inc.

Shuman Glenn & Stecker Investigates Corcept Therapeutics, Inc.

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2020 Results - Earnings Call Transcript

MENLO PARK, Calif., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended June 30, 2020.

Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

MENLO PARK, Calif., July  28, 2020  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of its first patient in GRADIENT, a double-blind, placebo-controlled, Phase 3 trial of relacorilant in patients with Cushing’s syndrome caused by adrenal adenomas or hyperplasia.

Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing’s Syndrome of Adrenal Origin

MENLO PARK, Calif., July  23, 2020  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced the completion of enrollment in its controlled, Phase 2 trial of relacorilant combined with nab-paclitaxel (Abraxane®) in patients with metastatic, platinum-resistant ovarian cancer.

Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer

QuidelOrtho Corp

Veeva Systems

Vertex Pharmaceuticals

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Why Biotechs Are Moving Up Among 4 Top-Rated Health Care Stocks

Alexion Pharma

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
The post These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why appeared first on Investor's Business Daily.

These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why

Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.

Corcept Begins Enrollment in Phase III Pancreatic Cancer Study

MENLO PARK, Calif., June  30, 2020  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of the first patient in RELIANT, an open-label, Phase 3 trial of relacorilant in combination with nab-paclitaxel (Celgene’s medication, Abraxane®) in patients with metastatic pancreatic cancer.

Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

MENLO PARK, Calif., June  15, 2020  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, will present novel genomic data from patients with adrenocortical carcinoma at the 2020 American Association of Cancer Research (AACR) Annual Meeting. This year's annual meeting will be held in a virtual format starting June 22. Following its presentation, a copy of our poster will be available at the Research & Pipeline / Publications tab of our website.

News for Corcept Therapeutics Stock (CORT)